• EE695 Applying NICE's Disease Severity Modifier to the Context of Cancer Screening

    Dec 1, 2024, 00:00

  • EE756 Cost-Utility Analysis of Single-Inhaler Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate for Maintenance Therapy in Patients With Moderate-to-Severe Uncontrolled Asthma in China

    Dec 1, 2024, 00:00

  • EPH269 Changes in the Prevalence of Early Onset Dementia and Mild Cognitive Impairment in 2020-2023 Compared to 2010-2013 in German General Practices

    Dec 1, 2024, 00:00

  • HTA144 Is Pediatric Indication an Implicit Driver of the French HTA Appraisal Outcomes?

    Dec 1, 2024, 00:00

  • EE717 Influence on Antibiotic Prescribing and Cost Effects Through Standardized Implementation of PoC Testing in Adults With Sore Throats in Standard SHI Care

    Dec 1, 2024, 00:00

  • HTA128 Kaleidoscope (QALY in Scope): A Conceptual Framework for Contextualizing Value via Dynamic Cost-Effectiveness Threshold

    Dec 1, 2024, 00:00

  • CO63 Clinical Meaningfulness of Improvements in Quality of Life Observed With Garadacimab Treatment in Patients Living With Hereditary Angioedema: Results From the Pivotal Phase 3 (VANGUARD) Study

    Dec 1, 2024, 00:00

  • EE249 The Hidden Burden of Migraine: Analysis Using a Fiscal Framework in Colombia

    Dec 1, 2024, 00:00

  • EE525 Exploring the Implementation of Polygenic Risk Scoring in Alzheimer's Disease: An Early Value Model

    Dec 1, 2024, 00:00

  • EE446 Health and Budget Impact of Lenacapavir for HIV Pre-Exposure Prophylaxis in South Africa, Western Kenya, and Zimbabwe: A Modeling Analysis

    Dec 1, 2024, 00:00

  • EPH278 Trends in Epidemiology and Mortality of Patients With Lung Cancer in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • HTA118 Benefit vs Uncertainties: The Potential Impact of Joint Clinical Assessment (JCA) on Market Access and Reimbursement of Novel Drugs

    Dec 1, 2024, 00:00

  • HPR185 Performance-Based vs Finance-Based Managed Entry Agreements (MEAs): Global Trends and Challenges

    Dec 1, 2024, 00:00

  • HTA201 A Quantitative Assessment of the Economic Decision Drivers Outlined in HTA Outcomes Through Stratification and Sentiment Analysis: Evidence From Canada, England, Scotland, and Sweden

    Dec 1, 2024, 00:00

  • HSD136 Assessing Gaps in the Timely Referral of Patients for a Rare Disease Diagnosis: A Cross-Sectional Survey of Physicians in Europe

    Dec 1, 2024, 00:00

  • EE334 Use of Disease Analogues to Inform Health-Economic Parameters for Economic Evaluations of Rare Diseases: A Case-Study of Multiple System Atrophy

    Dec 1, 2024, 00:00

  • CO36 Placebo Effect for Clinical Remission in Induction and Maintenance Treatment in Crohn's Disease: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2024, 00:00

  • EE703 Comparison of Administrative Burden Associated With Kesimpta and Ocrevus Among Multiple Sclerosis (MS) Clinics in Canada

    Dec 1, 2024, 00:00

  • HSD36 Medical Devices Index 2023: Access and Sourcing in Portuguese Hospitals, Challenges and Opportunities

    Dec 1, 2024, 00:00

  • HPR152 A Comparison of the Acceptability of Evidence in the New Joint Clinical Assessment and Nine European Union Countries

    Dec 1, 2024, 00:00

  • HPR151 Analysis of the Outcomes of the Hearings of the Transparency Committee in France

    Dec 1, 2024, 00:00

  • HTA37 Reimbursement Process of Orphan Drugs in the Czech Republic After Legislation Change

    Dec 1, 2024, 00:00

  • EE673 Cost-Effectiveness Analysis of ARNI Compared to ACEI Among Heart Failure Patients With Reduced Ejection Fraction in Malaysia

    Dec 1, 2024, 00:00

  • HSD65 Optimizing Management and Outcomes of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) in Spain: BEWAYAPDS Project

    Dec 1, 2024, 00:00

  • HPR78 Opportunities and Barriers for the Implementation of the Personalized Medicine in Lithuania

    Dec 1, 2024, 00:00

  • EPH72 Transferability of Health Economic Eviden A Quantitative Country Comparison of Acute Respiratory Infection and Influenza-like-Illness Incidence

    Dec 1, 2024, 00:00

  • HPR167 Stakeholders' Perspectives on the Use of Patient Registry Data for Decision-Making on Medicines: A Cross-Sectional Survey

    Dec 1, 2024, 00:00

  • HPR50 The Impact of First Generic Entrance on Public Spending and Medicines Cost: A Case Study in Bulgaria

    Dec 1, 2024, 00:00

  • HPR126 Health Economics Centers and Support in SUS Management: A Report of Successful Experiences

    Dec 1, 2024, 00:00

  • CO23 An Indirect Comparison of Polihexanide 0.08% Versus Currently Used Treatments for Acanthamoeba Keratitis

    Dec 1, 2024, 00:00

  • HPR131 Needs and Challenges of the Payor and Regulatory Community Towards Integrating Obesity Into a Chronic Care Framework

    Dec 1, 2024, 00:00

  • EE723 Healthcare Resource Utilization Among Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in the Netherlands

    Dec 1, 2024, 00:00

  • EPH144 Buzz and Bite: The Rise of Mosquito-Borne Diseases Across Europe in Recent Years

    Dec 1, 2024, 00:00

  • EPH65 Analyzing the Effect of Meteorological Factors on Stroke Inciden The Case of Hungary

    Dec 1, 2024, 00:00

  • EE259 Pharmacists as Advocators for Influenza Vaccination in Elderly Patients: A Cost-Effectiveness Analysis

    Dec 1, 2024, 00:00

  • CO107 Indirect Treatment Comparison of Efgartigimod vs Immunoglobulins in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    Dec 1, 2024, 00:00

  • HPR44 Analysis of Anatomical Therapeutic Chemical (ATC) Classification and Therapeutic Area of Orphan Medicinal Products (OMP) vs Reimbursement for These Drugs in 11 European Countries

    Dec 1, 2024, 00:00

  • CO6 Projected Public Health Benefits of Increasing Vaccine Coverage for COVID-19 Among Adults ≥ 50 Years of Age in the United States

    Dec 1, 2024, 00:00

  • HTA22 Are NICE Methods Appropriate for Rare Diseases That Do Not Meet the HST Criteria?

    Dec 1, 2024, 00:00

  • EPH211 Analysis of Regional Differences in Female Infertility in Hungary in the Last Decade

    Dec 1, 2024, 00:00

  • CO70 A Systematic Literature Review and Feasibility Assessment for Indirect Treatment Comparison of Insulin Icodec with Other Basal Insulins in Patients With Type 2 Diabetes

    Dec 1, 2024, 00:00

  • HTA87 Exploring the Effects of the European Union (EU) Joint Health Technology Assessment (HTA) on the Launch Sequencing of New Drugs and Identifying Opportunities to Improve the Availability of Reimbursed Medicines in Europe

    Dec 1, 2024, 00:00

  • EE611 Cost-Effectiveness of Icosapent Ethyl in Patients With Recent Acute Coronary Syndrome in Catalonia

    Dec 1, 2024, 00:00

  • PT14 Economic Evaluation of an eHealth Application Fostering Palliative Care for Cancer Patients in Greece

    Dec 1, 2024, 00:00

  • EPH136 Analyzing the Effect of Body Weight on Mortality After Hip Fracture

    Dec 1, 2024, 00:00

  • PT26 From Clinical Assessment to Drug Reimbursement in Spain: Current Timelines and Potential Impact From the Joint Clinical Assessment

    Dec 1, 2024, 00:00

  • CO75 A Systematic Literature Review on the Efficacy of Pharmacological Interventions in Ataxia

    Dec 1, 2024, 00:00

  • HTA60 ASCO Value Framework and ESMO-Magnitude of Clinical Benefit Scale in the Incorporation of New Technologies: Case Study and Challenges in the Private Health Care System

    Dec 1, 2024, 00:00

  • EE343 Cost-Effectiveness Analysis of Resmetirom for the Treatment of Adults With Noncirrhotic NASH and Moderate-to-Advanced Liver Fibrosis in the US: Integrating the Dual NASH Resolution and Fibrosis Improvement Endpoints

    Dec 1, 2024, 00:00

  • CO103 Characteristics of Patients With Ehlers-Danlos Syndromes (EDS): Analysis of US Real-World Data

    Dec 1, 2024, 00:00

  • EE630 Effects and Costs of Country-Level Hepatitis C Virus Elimination in China: A Modelling Study

    Dec 1, 2024, 00:00

  • EE361 Long-Term Remission (LTR) Assumptions in Health Technology Assessments (HTAs) of Bispecific Treatments for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Following Two or More Lines of Systemic Therapy (3L+)

    Dec 1, 2024, 00:00

  • EPH146 Progression to Metastatic Breast Cancer According to Stage and Biomarker Status at Diagnosis in Denmark: A Register-Based Cohort Study

    Dec 1, 2024, 00:00

  • EE272 Using Structured Expert Elicitation in Cost-Effectiveness Analysis: An Exploratory Case Evaluating Selpercatinib for Thyroid Cancer in Norway

    Dec 1, 2024, 00:00

  • EE311 Evaluating the Cost-Effectiveness of Ruxolitinib for the Treatment of Polycythaemia Vera Patients That Are Resistant/Intolerant to Hydroxycarbamide/Hydroxyurea in England and Wales

    Dec 1, 2024, 00:00

  • HTA97 Impact of EMA's Conditional Marketing Authorizations on the Benefit Assessment Validity Period in Germany: Insights From 2017-2023

    Dec 1, 2024, 00:00

  • CO33 Payer-Reported Unmet Need Burden Post Allogeneic Hematopoietic Cell Transplantation (HCT) Due to Poor Graft Function (PGF) and Characteristics of an Ideal Treatment for PGF

    Dec 1, 2024, 00:00

  • HTA29 The Use of Real-World Evidence in NICE Health Technology Appraisals: A Quantitative Review of Submissions to NICE Between 2022 and 2024

    Dec 1, 2024, 00:00

  • HPR123 Assessment of Price Reduction Prediction Based on the Lasted Reimbursement Drug Renewal Rules in China

    Dec 1, 2024, 00:00

  • HPR11 The Horizon of Oncology: Estimating the Impact of New EU Regulation on Health Technology Assessment for 2025-2028

    Dec 1, 2024, 00:00

  • EPH141 Intersecting Challenges: Progressive Multifocal Leukoencephalopathy (PML) and Underlying Diseases

    Dec 1, 2024, 00:00

  • CO90 Matching-Adjusted Indirect Comparison of Efficacy and Safety for Lebrikizumab, Dupilumab, and Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis Not Adequately Controlled or Non-eligible for Cyclosporine

    Dec 1, 2024, 00:00

  • HSD120 Evaluating Pre-Treatment Patient Pathways in Early Alzheimer's Disease Management: A Claims Data Analysis in Germany

    Dec 1, 2024, 00:00

  • HPR30 Implementation of a National Value-Based Insurance Drug Formulary in the Saudi Private Health Sector

    Dec 1, 2024, 00:00

  • HSD55 Impact of a Novel Bone Health Dedicated Outpatient Clinics for Managing Cancer Treatment-Induced Bone Loss: A Propensity-Score Matching Study

    Dec 1, 2024, 00:00

  • EPH69 Analysis of Influenza Vaccination Coverage and Vaccine Effectiveness in Population Aged 65 and Over in Ambulatory Medicine in France From 2016 to 2019: A Study Based on Real-World Data

    Dec 1, 2024, 00:00

  • P6 Projected Increase of the Clinical, Economic, Societal, and Environmental Burdens of Chronic Kidney Disease in Switzerland: Insights from Impact-CKD

    Dec 1, 2024, 00:00

  • HPR9 Delayed Access to Innovative Medicines in Romania: A Comprehensive Analysis of the Reimbursement Processes (2015-2024)

    Dec 1, 2024, 00:00

  • EE823 The Impact of Weight Loss in a Japanese Cohort of Individuals Living with Obesity

    Dec 1, 2024, 00:00

  • EPH259 Mortality in People Diagnosed With Progressive Multifocal Leukoencephalopathy: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE663 Budget Impact Analysis of Fracture Risk Assessment (FRAX) Based Treatment Strategy Selection in Patients With Glucocorticoid-Induced Osteoporosis (GIOP)

    Dec 1, 2024, 00:00

  • EE263 Screening for Type 2 Diabetes Mellitus: A Systematic Review of Economic Evaluations

    Dec 1, 2024, 00:00

  • CO96 Anti-Obesity Medications and Related Osteoarthritis Risk Among Patients With Obesity

    Dec 1, 2024, 00:00

  • EPH205 Overall Survival in Individuals Diagnosed With Progressive Multifocal Leukoencephalopathy

    Dec 1, 2024, 00:00

  • EE656 Challenges in Health-Economic Modeling of Phenylketonuria (PKU): A Targeted Review of HTA Evaluations

    Dec 1, 2024, 00:00

  • EE561 Healthcare Resource Utilization Among Patients With Transfusion-Dependent Beta-Thalassemia in the Netherlands

    Dec 1, 2024, 00:00

  • HTA213 Conceptual Approach for a Value-Based Assessment Tool in Oncology and Its Application in Advanced Triple Negative Breast Cancer in Colombia

    Dec 1, 2024, 00:00

  • EPH80 Impact of the COVID-19 Pandemic on Arterial Hypertension Monitoring and Control in Portugal

    Dec 1, 2024, 00:00

  • EE496 Relugolix/Estradiol/Norethisterone Compared to Tranexamic Acid for Symptomatic Uterine Fibroids in Premenopausal Women (20 to 40 YEAR Old): A Cost-Utility Analysis

    Dec 1, 2024, 00:00

  • EE261 Economic Evaluation of Dupilumab Versus Standard of Care for the Treatment of Adult Patients With Moderate-to-Severe Prurigo Nodularis in the United States

    Dec 1, 2024, 00:00

  • EPH97 Characteristics of Cannabis-Based Consumer Health Products Users in Community Pharmacies in Portugal

    Dec 1, 2024, 00:00

  • CO64 Systematic Review of Methimazole in Graves' Disease Management: Treatment Variations and Efficacy Outcomes

    Dec 1, 2024, 00:00

  • HTA179 A Targeted Review of Treatment Beyond Progression in NICE HTA Oncology Submissions

    Dec 1, 2024, 00:00

  • HTA160 Structured Expert Elicitation in HTA Submissions: A Practical Guide Using the Example of Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma

    Dec 1, 2024, 00:00

  • HSD119 How a Government Policy Can Have a Positive Impact on Women's Choice of Contraception: A Study of Irish Pharmacy Sales Data Between the Years 2021-2024

    Dec 1, 2024, 00:00

  • EE733 Budget Impact Analysis of Metreleptin in Patients With Lipodystrophy in Saudi Arabia

    Dec 1, 2024, 00:00

  • EE651 Evaluating the Cost-Effectiveness of Dabrafenib and Trametinib for the Treatment of Pediatric Patients With Low-Grade Glioma Requiring Systemic Treatment in England and Wales

    Dec 1, 2024, 00:00

  • EPH126 Assessment of the Effects of Metabolism of Caffeine on Reaction Time by Age Group

    Dec 1, 2024, 00:00

  • EE560 Potential Budget Impact of Using a Cyanoacrylate Polymer Barrier Film Versus Traditional Method for the Prevention of Incontinence-Associated Dermatitis in a Hospital Setting in New Zealand

    Dec 1, 2024, 00:00

  • PT27 Time to Reimbursement in Ireland: Utilizing Regression Analysis to Assess Factors Contributing to Overall Timelines

    Dec 1, 2024, 00:00

  • CO46 Cognitive Assessments in Drug Development in Dementia and MCI: Clinical Trial Landscape Review and Recommendations for Future Neurodegenerative Studies

    Dec 1, 2024, 00:00

  • EE429 Insights From an Expert Advisory Board: The Trends Driving Changes in Managed Care

    Dec 1, 2024, 00:00

  • EE237 Cost-Minimization Analysis for Soliqua in the Treatment of T2DM in Turkiye

    Dec 1, 2024, 00:00

  • EE271 Cost-Effectiveness Analysis of RSVPreF3 OA Vaccine for Adults 60 Years or Older in Austria

    Dec 1, 2024, 00:00

  • HTA50 Characterizing Evidentiary Critiques in HTA Decision-Making for Treatments Indicated for Overweight and Obesity

    Dec 1, 2024, 00:00

  • EE293 Cost-Effectiveness of Diagnostic Testing for Hepatitis Delta in the United Kingdom

    Dec 1, 2024, 00:00

  • EE782 The Landscape of Pre-Exposure Prophylaxis (PrEP) in Brazil: Challenges, Advances, and Opportunities As a Public Health Strategy in the Battle Against HIV/AIDS

    Dec 1, 2024, 00:00

  • CO52 Relationship Between Hemoglobin Levels and EQ-5D-5L Utility Index in Patients With Cold Agglutinin Disease

    Dec 1, 2024, 00:00

  • HPR242 Lump-Sum Envelopes: High Predictability for Payers (Healthcare Product Pricing Committee – CEPS) and Minor Contribution for Companies

    Dec 1, 2024, 00:00

  • EPH147 Situational Analysis of Sexual Health in Cartagena and Bolívar, Colombia 2023

    Dec 1, 2024, 00:00

  • EE491 A Budget Impact Analysis of a New Treatment for Adults With Homozygous Familial Hypercholesterolaemia

    Dec 1, 2024, 00:00

  • PT7 Reassessment Dynamics of Orphan Drugs in Germany’s Benefit Assessment Process

    Dec 1, 2024, 00:00

  • EPH276 Predicting the Public Health Impact of Different Adult Pneumococcal Vaccines in Japan Using a Dynamic Transmission Model

    Dec 1, 2024, 00:00

  • EE766 Burden of HPV-Related Diseases in the Czech Republic: Model-Based Study

    Dec 1, 2024, 00:00

  • Three Pillars of Support for Orphan Drug Programs: Individual Valuations, Societal Valuations, and Anonymous Altruism [Editor's Choice]

    Dec 1, 2024, 00:00

  • EE426 Cost-Effectiveness of Switching From PCV13 to PCV20 in the Portuguese Childhood National Immunization Program

    Dec 1, 2024, 00:00

  • HTA47 The Difference Between PICO Evaluation Across Australia, EU4, and UK

    Dec 1, 2024, 00:00

  • EE729 Clinical and Economic Impact of a Tri-Layer Hybrid Biomaterial vs Synthetic Mesh for Ventral Hernia Repair in Australia: A Cost-Consequence and Budget Impact Analysis

    Dec 1, 2024, 00:00

  • EPH167 Trends in Epidemiology and Mortality of Patients With Hypertension in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • HTA189 Alignment of EU HTA and Member State Clinical Assessments and the Potential Impact on Value Perception

    Dec 1, 2024, 00:00

  • HPR182 Innovative Contracts: A Solution to Manage the ATMPs Associated Uncertainty

    Dec 1, 2024, 00:00

  • EPH148 Medical Costs of Adults With COVID-19 in Guatemala During the Endemic Phase: A Micro-Costing Study

    Dec 1, 2024, 00:00

  • EE390 Potential Budget Impact of Using a Cyanoacrylate Polymer Barrier Film Compared to Traditional Methods for the Management of Incontinence-Associated Dermatitis for Residents of a Skilled Nursing Facility

    Dec 1, 2024, 00:00

  • HSD91 Integrated Care Process and Pharmacological Prescription for Patients With Hypercholesterolemia or Mixed Dyslipidemia at High or Very High Cardiovascular Risk in Catalonia

    Dec 1, 2024, 00:00

  • EE599 Estimating the Potential Lifetime Health and Economic Impact of V116 on Pneumococcal Disease in Mexico

    Dec 1, 2024, 00:00

  • HTA134 Implications of Indication Expansions on Pricing and Reimbursement and How This Differs Between EU4 and UK Markets

    Dec 1, 2024, 00:00

  • CO78 High-Efficacy Therapies (HETs) First Versus an Escalation Approach in Multiple Sclerosis: A Targeted Literature Review

    Dec 1, 2024, 00:00

  • P4 Bias Reduction in Indirect Treatment Comparison of Time-to-Event Outcomes: A Case Study on Application of ML-NMR Versus MAIC Using Simulated Dataset

    Dec 1, 2024, 00:00

  • HTA167 Use of Real-World Evidence in Health Technology Reassessments Across Six Health Technology Assessment Agencies

    Dec 1, 2024, 00:00

  • HPR29 Impact of Diagnosis-Related Groups (DRG) Payment on the Quality and Efficiency of Peripheral Arterial Disease (PAD) Care: A Mixed-Methods Study

    Dec 1, 2024, 00:00

  • EE403 The Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in Germany

    Dec 1, 2024, 00:00

  • EPH40 Challenges and Issues of Patients Living With HIV in Algeria: Current Epidemiological Situation

    Dec 1, 2024, 00:00

  • Editor Message

    Dec 1, 2024, 00:00

  • EE280 Impact of COVID-19 on Healthcare Utilization and Costs: A Detailed Analysis From Inpatient and Outpatient Perspectives

    Dec 1, 2024, 00:00

  • HSD24 Estimating the Global and EU27+UK Prevalence of Patients With Cancer in Palliative Care and Patients in Two Neurodegenerative Disorders Potentially Benefiting From Cannabinoid-Based Medicines

    Dec 1, 2024, 00:00

  • EE303 Adult Immunization With Tetanus, Diphtheria, and Pertussis Vaccine for at-Risk Populations (Asthma, COPD, HIV) for the Prevention of Pertussis in Colombia

    Dec 1, 2024, 00:00

  • HSD5 Real-World Survey on Treatment Pathways and Patterns for Patients With Primary Immune Complex Membranoproliferative Glomerulonephritis

    Dec 1, 2024, 00:00

  • HSD97 Clinicopathological Features Associated With the High Risk of Recurrence of Stage II Colorectal Cancer: Variability Among Guidelines and Studies, and Potential Implications for Market Access

    Dec 1, 2024, 00:00

  • EPH230 Geographic Variation in Routine Childhood Vaccination Using Real-World Eviden Pre- and Post- COVID-19 Pandemic

    Dec 1, 2024, 00:00

  • EE495 Cost-Effectiveness of a Comprehensive HBV Screening and Management Program in China: A Real-World Data Analysis From Huazhou City

    Dec 1, 2024, 00:00

  • CO26 Encorafenib Plus Binimetinib Versus Dabrafenib Plus Trametinib in First-Line for Patients With Metastatic Non-Small Cell Lung Cancer Harboring BRAF V600E Mutation: Matching Adjusted Indirect Comparison of Pharos and BRF113928

    Dec 1, 2024, 00:00

  • EPH70 Association Between Sleep Disorders and Subsequent Depression in Children and Adolescents: A Retrospective Cohort Study With 62,796 Patients in Germany

    Dec 1, 2024, 00:00

  • HTA225 Optimizing HTA Outcomes in Cost-Effectiveness Markets: A Case Study of Axicabtagene Ciloleucel

    Dec 1, 2024, 00:00

  • EPH207 Incidence and Prevalence of Idiopathic Pulmonary Fibrosis (IPF): A Systematic Literature Review and Meta-Analysis

    Dec 1, 2024, 00:00

  • EE289 Cost of Hepatocellular Carcinoma in Türkiye: Results of a Delphi Panel Analysis

    Dec 1, 2024, 00:00

  • EPH139 Prevalence and Disease Burden of Disease-Related Malnutrition in Hospitalized Patients in Spain

    Dec 1, 2024, 00:00

  • EE409 The Economic Impact of Early Comprehensive Genomic Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer Patients: Real World Evidence From a Brazilian Private Healthcare Provider Database

    Dec 1, 2024, 00:00

  • HTA142 Use of External Control Arms in Reimbursement Submissions: A Review of CAR-T Appraisals by NICE and CDA

    Dec 1, 2024, 00:00

  • EE655 Cost-Effectiveness Analysis of Eladocagene Exuparvovec for the Treatment of Aromatic L-Amino Acid Decarboxylase Deficiency (AADCd) From a United States (US) Perspective

    Dec 1, 2024, 00:00

  • EE819 How Can Discrete Choice Experiment Method Improve Patient Care and Engagement? An Example in the Field of Fertility

    Dec 1, 2024, 00:00

  • HPR4 Analyzing the Impact of EU5 and UK Pricing Reforms: A Pathway to Adaptation in an Evolving Policy Landscape

    Dec 1, 2024, 00:00

  • EE557 A Systematic Review of Productivity Gain/Loss in Health Economic Evaluations: An Element for Value Assessment of Innovative Treatments

    Dec 1, 2024, 00:00

  • EE499 Health Resource Utilization (HRU) and Costs of Patients With Relapsed/Refractory Multiple Myeloma (RRMM) in the United States (US): A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE632 Early Cost-Effectiveness of SPECTRISTM (Gamma Band Stimulation) in Mild-Moderate Alzheimer's Disease Patients

    Dec 1, 2024, 00:00

  • HSD33 Over a Decade of Trends in Gabapentinoid Prescribing and Daily Doses Among Patients Taking Opioids for Pain Management in Malaysia (2010-2020)

    Dec 1, 2024, 00:00

  • HTA13 Is Carer Burden a Given When Modelling Spinal Muscular Atrophy? Examining NICE Submissions

    Dec 1, 2024, 00:00

  • EE649 Prerequisites for Cost-Effective Home Blood Pressure Telemonitoring: Insights From an Early Health Economic Analysis

    Dec 1, 2024, 00:00

  • EE824 Are Standard Economic Evaluations Suitable for Evaluating Life-Extending Innovations in Kidney Care?

    Dec 1, 2024, 00:00

  • EE732 From Pipeline to Pricing Reimbursement: Economic Impact and Access Challenges of Upcoming Gene Therapies

    Dec 1, 2024, 00:00

  • HPR70 Distribution of Prescriptions From Medical Institutions to Pharmacies in Japan: An Analysis of Health Insurance Claims Database

    Dec 1, 2024, 00:00

  • HSD137 The Value Proposition of Remote Monitoring in Heart Failure: Pains and Gains Towards Patients’ Adoption

    Dec 1, 2024, 00:00

  • HPR21 The Impact of the Health Act (Pricing and Supply of Medical Goods) (2013) on the Pricing of Medicines in Ireland

    Dec 1, 2024, 00:00

  • EPH1 Universal Health Coverage and Education Are the Decisive Socio-Economic Disparities in Cervical Cancer Mortality in the Dominican Republic: A Multi-Dimensional Ecological Approach in a Middle-Income Caribbean Country

    Dec 1, 2024, 00:00

  • EPH138 Identifying and Profiling Patients With Heart Failure in a Population-Based Cohort Through Linkage of Primary and Secondary Care Data

    Dec 1, 2024, 00:00

  • EPH239 Positive Airway Pressure (PAP) Therapy in Obstructive Sleep Apnea (OSA): Modeling of 20 Year Mortality and Hospitalizations

    Dec 1, 2024, 00:00

  • HPR25 Assessing Sustainable Biosimilar Competition: Current Trends and Impacts of Anti-TNF Biosimilar Competition in Europe

    Dec 1, 2024, 00:00

  • HPR86 Frequency and Variation of Clock-Stop During EMA Assessment for Oncology Products: Implication on JCA Timelines

    Dec 1, 2024, 00:00

  • HSD132 An Integral Approach to Assess the 3 Human Normal Immunoglobulin Formulations for Primary Immunodeficiency in Portugal: Combining Costs, Patient's Preferences, and HCP Choices

    Dec 1, 2024, 00:00

  • CO82 Long-Acting Somatostatin Analogues Treatment Patterns and Outcomes in Neuroendocrine Tumor Patients: An Italian Propensity Score Matched Cohort Study

    Dec 1, 2024, 00:00

  • EPH110 Trends in Epidemiology and Mortality of Patients With Colorectal Cancer in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • EE386 Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against Il-17A, Il-12/23 and Il-23 Inhibitors for the Treatment of Psoriatic Arthritis in Finland

    Dec 1, 2024, 00:00

  • HTA9 Cross Analysis of HAS Conclusions Amongst Products With an Economic Opinion Posted in 2023

    Dec 1, 2024, 00:00

  • HTA227 Evaluating the Importance of Patient Input in NICE Highly Specialized Technology (HST) Assessments: Insights From Review Reports

    Dec 1, 2024, 00:00

  • HPR238 FDA vs EMA a Comparison of New Chemical Entity Approvals: The Role of Start-Ups

    Dec 1, 2024, 00:00

  • EE304 Economic Evaluation of Mailing Self-Sampling qFIT Kits to Non-Participants in Colorectal Cancer Screening in the Czech Republic

    Dec 1, 2024, 00:00

  • HPR219 Studies on Health Economics and Outcomes From Türkiye Published in ISPOR by the Year 2024

    Dec 1, 2024, 00:00

  • P42 EQ-5D-5L Mapping Function Recently Recommended by NICE Is Likely to Generate Higher Utility Values

    Dec 1, 2024, 00:00

  • EE474 Valuation and Exploitation of Sick Leaves Identified in the French SNDS Database

    Dec 1, 2024, 00:00

  • CO97 Characterizing the Burden and Unmet Need of Antibody-Mediated Rejection

    Dec 1, 2024, 00:00

  • EE256 Darolutamide As a Leading Option to Manage Prostate Cancer

    Dec 1, 2024, 00:00

  • EE840 Assessing Direct Medical Costs of Stage IV NSCLC in Iraq From Public Payer Perspective

    Dec 1, 2024, 00:00

  • EPH257 Impact of Fragility Fractures in the Bolívar Department, Colombia

    Dec 1, 2024, 00:00

  • EPH154 Long-Term Incident Heart Failure After Acute Coronary Syndrome: A Population-Based Analysis

    Dec 1, 2024, 00:00

  • HTA210 Effectiveness of Generic Quality of Life (QoL) Questionnaires in Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD)

    Dec 1, 2024, 00:00

  • EE506 Budget Impact and Cost-Utility Analysis of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Renal Cell Cancer (aRCC) in Costa Rica

    Dec 1, 2024, 00:00

  • CO120 Assessment of Metformin Failure Among Patients With Type 2 Diabetes Mellitus at a Tertiary Care Center in Central India

    Dec 1, 2024, 00:00

  • EE746 Budget and Organizational Impact Models (OBIM) for Health Products in Europe: An Overview from 2014 to 2024

    Dec 1, 2024, 00:00

  • EPH175 Baseline Risk of Hospitalization and Death in a Nirmatrelvir/Ritonavir Treatment-Eligible Population With Mild-to-Moderate COVID-19 in the United States: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EPH159 Estimating the Remaining Chronic HCV Prevalence in Ireland: A Risk Population Modelled Approach Applied in Practice

    Dec 1, 2024, 00:00

  • HTA65 Exploring PICO Variations in Relapsed or Refractory DLBCL in the Context of the European Joint Clinical Assessment

    Dec 1, 2024, 00:00

  • EPH134 Home Sweet Hospital: Evaluating Evidence Gaps and Future Research Priorities for Hospital at Home

    Dec 1, 2024, 00:00

  • CO53 The Impact of Approved Anti-Obesity Medications on the Risk of Obstructive Sleep Apnea in Patients With Obesity: A Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • EE597 Budget Impact Analysis of Introducing Benralizumab for the Treatment of Eosinophilic Granulomatosis With Polyangiitis: A European Perspective

    Dec 1, 2024, 00:00

  • HTA74 Incorporating Environmental Sustainability Into Health Technology Assessments: Two Adapted Cost-Utility Analyses (CUA) of Insulin Icodec Versus Degludec for Type 2 Diabetes (T2D) Management in England

    Dec 1, 2024, 00:00

  • EE262 Cost-Consequence Analysis of Cabozantinib in Combination With Nivolumab in Treatment of First-Line Advanced Renal Cell Carcinoma in Germany: A Payer Perspective

    Dec 1, 2024, 00:00

  • HPR224 Utilization of Long-Term Care Before and After the 2015 Dutch National Reform: An Interrupted Time Series Analysis

    Dec 1, 2024, 00:00

  • Disclaimer

    Dec 1, 2024, 00:00

  • HTA96 The Increasing Use of Real-World Data in Health Technology Appraisals of Oncology Therapies: A Systematic Review

    Dec 1, 2024, 00:00

  • HPR127 The Cost Effectiveness of Collaborative Dementia Care for Alzheimer's Disease Relative to Disease Modifying Therapies

    Dec 1, 2024, 00:00

  • Cost-Effectiveness of Hepatocellular Carcinoma Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom

    Dec 1, 2024, 00:00

  • HTA185 From Plan to Action: Assessing the Impact of the NICE Real-World Evidence Framework Following Its Introduction in June 2022

    Dec 1, 2024, 00:00

  • EPH113 Impact of Indoor Air Pollution on Health in Low-to-Middle Income Countries

    Dec 1, 2024, 00:00

  • EE308 The Economic Burden of Alcohol in Belgium: Incremental Healthcare and Indirect Costs

    Dec 1, 2024, 00:00

  • EE778 Early Cost-Consequence Analysis of Comprehensive Genomic Profiling in a Metastasized Tumor-Agnostic Population

    Dec 1, 2024, 00:00

  • EE522 Cost-Effectiveness Analysis of Abrocitinib Versus Dupilumab in Adolescents With Severe Atopic Dermatitis in Spain

    Dec 1, 2024, 00:00

  • EE669 Analysis of the Costs and Carbon Footprint Associated With Reusable Flexible Cystoscopes: Implications for the Utilization of Single-Use Digital Flexible Cystoscopes

    Dec 1, 2024, 00:00

  • HPR117 The Economic Burden of Lung Cancer in Gree A Systematic Review of the Literature

    Dec 1, 2024, 00:00

  • EE763 Indirect Costs in 5 Types of Cancer in Adults in Mexico From 2024 to 2030

    Dec 1, 2024, 00:00

  • HTA42 Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines (2021-2022)

    Dec 1, 2024, 00:00

  • EPH14 Gastrointestinal Endoscopy Volume, Efficiency, and Safety Issues: A Case Report

    Dec 1, 2024, 00:00

  • HPR160 Integrating Healthcare System Value Into New Medicine Evaluations for Timely and Full Patient Access

    Dec 1, 2024, 00:00

  • HTA75 Payer Perceptions of Health Inequalities in Reimbursement Decision-Making: Results of a Global Survey

    Dec 1, 2024, 00:00

  • HPR140 Using Safety Engineered Intravenous Access Devices in Malaysia to Reduce Needle Stick Injuries: A Meta-Analytic Synthesis of Literature Health System Projection

    Dec 1, 2024, 00:00

  • EPH66 How Real Is Your Real-World Evidence (RWE)? Demonstration of the Need for Comprehensive Real-World Data (RWD) to Examine Patient Burden and Disease Journey in Patients With Sickle Cell Disease (SCD) in the United States (US)

    Dec 1, 2024, 00:00

  • P50 Technical Validation of an Environmental Model of Aurora EV-ICD: Recommendations to Guide Environmental Criteria in Health Technology Assessment

    Dec 1, 2024, 00:00

  • HPR177 Modeled Impact of Risk-Sharing Agreements on Costs for Hemophilia B Gene Therapy in Germany

    Dec 1, 2024, 00:00

  • HTA64 Leveraging Machine Learning for Predicting Health Technology Assessment Outcomes

    Dec 1, 2024, 00:00

  • EPH51 Evaluation of US/European Deprivation Indices Applications in Oncological, Health Economics, and Outcomes Research (HEOR) Studies

    Dec 1, 2024, 00:00

  • HSD44 Physical Therapy in Patients With Pulmonary Arterial Hypertension (PAH): Results From a German Claims Data Analysis

    Dec 1, 2024, 00:00

  • EPH37 Adult Vaccinations in Europe: Unfulfilled Potential

    Dec 1, 2024, 00:00

  • EE691 Cost Estimation of Managing Retinitis Pigmentosa in France in a Multi-Payer Environment From a Societal Perspective

    Dec 1, 2024, 00:00

  • HTA48 Evaluating the Relevance of Conditional Marketing Authorization for Successful HTA Outcomes in France

    Dec 1, 2024, 00:00

  • HPR52 Macroeconomic Regulation of Drug Expenditures in Europe: Lessons for the French Safeguard Clause From a Scoping Review

    Dec 1, 2024, 00:00

  • EPH130 The Humanistic Burden and Productivity Lost From Atopic Dermatitis in Central and Eastern European Countries

    Dec 1, 2024, 00:00

  • HSD134 Prescribers' Opinions, Preferences and Attitudes on Deprescribing for Patients With Diabetes in China: A Nationwide Cross-Sectional Survey

    Dec 1, 2024, 00:00

  • CO38 Burden and Trends of COPD Exacerbations in France Before and During the Pandemic

    Dec 1, 2024, 00:00

  • HTA226 Lack of Face Validity in Health Technology Assessments: Systematic Review of NICE Assessments and Lessons Learned

    Dec 1, 2024, 00:00

  • EE722 Assessing Healthcare Resource Use and Burden Among an Older Population of Patients With Respiratory Syncytial Virus in Five European Countries Using Real-World Data

    Dec 1, 2024, 00:00

  • HTA137 The Changing Landscape of Health Technology Assessment (HTA) in the Asia-Pacific (APAC) Region: Advances, Challenges, and Future Goals

    Dec 1, 2024, 00:00

  • The Impact of Additive Population(s), Intervention, Comparator(s), and Outcomes in a European Joint Clinical Health Technology Assessment

    Dec 1, 2024, 00:00

  • Does Real Option Value Influence Oncologists’ Treatment Recommendations? A Survey of US Oncologists

    Dec 1, 2024, 00:00

  • EE757 Cost-Effectiveness of DNA Methylation as Triage for Cervical Cancer Screening in Hong Kong: A Modelling Study

    Dec 1, 2024, 00:00

  • EE442 Cost-Utility Analysis and Efficiency Frontier Approach of Tafasitamab in Brazilian Private Healthcare System Perspective

    Dec 1, 2024, 00:00

  • HPR68 How to Overcome the Remaining Challenges for Successful Implementation of the EU HTA Regulation: Key Insights From the 2023 European Access Academy Spring Convention and Survey

    Dec 1, 2024, 00:00

  • HTA106 How Has Treatment Switching Been Accounted for? Insights From NICE Appraisals

    Dec 1, 2024, 00:00

  • EPH71 A Systematic Review and Meta-Analysis of Interval Cancer of Stool Testing for Colorectal Cancer Screening

    Dec 1, 2024, 00:00

  • P13 Development of a Goal Attainment Scale (GAS) and Global Impression (GI) Items for Use As Outcome Measures in Intervention Studies in Pediatric Autism

    Dec 1, 2024, 00:00

  • Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data

    Dec 1, 2024, 00:00

  • EE301 Cost-Effectiveness Analysis of Pembrolizumab in Combination With Lenvatinib for the Treatment of Advanced Second-Line Endometrial Cancer

    Dec 1, 2024, 00:00

  • EE836 Cost-Effectiveness of Zolbetuximab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Adenocarcinoma in Taiwan

    Dec 1, 2024, 00:00

  • EE337 Cost-Effectiveness of [177Lu]Lu-PSMA-617 in Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

    Dec 1, 2024, 00:00

  • EPH183 Utilization and Expenditure on Medicines for the Prevention and Treatment of Osteoporosis: A Changing Landscape

    Dec 1, 2024, 00:00

  • HTA184 Uncertainty Appraisal in Economic Opinions of the French National Authority for Health

    Dec 1, 2024, 00:00

  • HTA69 Vaccines and EU HTA: Exploring Misalignments Between Joint Clinical Assessment Requirements and a Hypothetical Vaccine Evidence Package

    Dec 1, 2024, 00:00

  • EE240 Evaluating the Impact of Matched-Adjusted Indirect Comparisons on Propagated Uncertainty in Economic Outcomes

    Dec 1, 2024, 00:00

  • HSD95 Economic Results of a Model for the Detection of Pharmacological Inefficiencies in Patients With Chronic Diseases

    Dec 1, 2024, 00:00

  • EE755 Substantial Healthcare Resource Utilization in Patients Diagnosed With Viral Lower Respiratory Tract Disease in Spain

    Dec 1, 2024, 00:00

  • EE528 Cost-Effectiveness Analysis of the TAK-003 Dengue Vaccine Introduction in Argentina

    Dec 1, 2024, 00:00

  • HTA165 A Comparative Analysis of Reimbursement Outcomes for Orphan Drugs Between EU and Non-EU Countries

    Dec 1, 2024, 00:00

  • EPH31 Incidence of Pulmonary Nodules (PNs) During the Coronavirus Disease (COVID-19) Pandemic in the United States (US)

    Dec 1, 2024, 00:00

  • EPH61 Sex-Related Disparities in Chronic Cough Reported by Adults in the United States

    Dec 1, 2024, 00:00

  • CO91 Validation of Clinical Response Rates Extrapolated With Dose-Response Estimation Methods in Chronic Hepatitis Delta

    Dec 1, 2024, 00:00

  • EE518 Economic Evaluations of Anifrolumab for the Management of Patients Affected by Systemic Lupus Erythematosus (SLE) in Italy

    Dec 1, 2024, 00:00

  • HPR207 How Long Is Long Enough? Data Collection Duration for Medicines in Managed Access in England

    Dec 1, 2024, 00:00

  • EPH158 Assessing the Public Health Benefit of a mRNA-Based Respiratory Syncytial Virus Vaccine (mRNA-1345) Among Adults ≥65 Years in France

    Dec 1, 2024, 00:00

  • EE585 Increasing Conscious Sedation Use for Dental Treatments: A Cost and Consequences Analysis

    Dec 1, 2024, 00:00

  • EE653 Cost-Effectiveness of Adjuvant Olaparib for Patients With Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Breast Cancer in Portugal

    Dec 1, 2024, 00:00

  • EE527 Economic Evaluation of Using Romiplostim for Early Immune Thrombocytopenia in Qatar

    Dec 1, 2024, 00:00

  • EE568 Economic Evaluation of the Co-Formulated Antiretroviral Efavirenz 400mg/Lamivudine/Tenofovir Disoproxil Fumarate for the Treatment of HIV-1 Infection in Adult Patients From the Perspective of the Mexican Public Health System

    Dec 1, 2024, 00:00

  • EE421 A Budget Impact Analysis of Azelastine Hydrochloride/Fluticasone Propionate (AzeFlu) Nasal Spray Suspension for Patients With Allergic Rhinitis (AR) in the Kingdom of Saudi Arabia

    Dec 1, 2024, 00:00

  • HSD58 Care Pathway of Patients With Neovascular Age-Related Macular Degeneration Treated by Anti-VEGF in France, Using Clustering Analysis Combined With Optimal Matching

    Dec 1, 2024, 00:00

  • HTA54 Review of Cell and Gene Therapies by NICE, HAS, and G-BA: How Did They Fare?

    Dec 1, 2024, 00:00

  • EE837 Cost Effectiveness of Nirsevimab and Maternal RSVpreF Vaccine for Prevention of Respiratory Syncytial Virus Disease Among Infants in the United States

    Dec 1, 2024, 00:00

  • CO133 Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients With Obesity: A Bayesian Network Meta-Analysis of GLP-1 RCTs

    Dec 1, 2024, 00:00

  • HTA232 Review of Real-World Evidence (RWE) in Marketing Authorization Applications (MAAs) Highlight Differences in Evidentiary Standards Among Regulatory and Health Technology Assessment (HTA) Bodies

    Dec 1, 2024, 00:00

  • PT25 Potential for Standardization in Economic Assessment Across HTA Bodies: A Case Study in First-Line Treatments of Non-Small Cell Lung Cancer

    Dec 1, 2024, 00:00

  • EE244 Economic Burden of Grade 3+ Adverse Event Management Associated With Dato-DXd and Docetaxel-Containing Regimens in Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: A European and USA Analysis

    Dec 1, 2024, 00:00

  • EE507 Deriving Decision Uncertainty Associated With Calibration Target Data: A Value of Information Approach

    Dec 1, 2024, 00:00

  • HSD21 The Impact on Health Service Delivery of Providing an Alternative Telephone Pathway for Acute But Non-Urgent Healthcare Needs: A Scoping Review of International Practice

    Dec 1, 2024, 00:00

  • HSD76 Treatment Utilization and Treatment Duration of Patients With Psoriasis Diagnosed With Psoriatic Arthritis in a US Commercial Administrative Claims Database

    Dec 1, 2024, 00:00

  • EPH135 Real-World Prescribing Patterns of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists in Germany

    Dec 1, 2024, 00:00

  • EE500 Global Economic Burden of Retinitis Pigmentosa (RP): A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EPH213 A Real-World Evidence Study Describing Characteristics of Patients Receiving a CVD Risk Assessment in Primary Care in England Between 2013 and 2023

    Dec 1, 2024, 00:00

  • HTA203 Dynamic Vaccine Valuation: A Method Framework for Early Health Technology Assessment, Driving Innovation, and Implementation Strategies

    Dec 1, 2024, 00:00

  • CO27 Comparative Effectiveness of the mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Canadians: A Systematic Literature Review and Meta-Analysis Using the Grade Framework

    Dec 1, 2024, 00:00

  • HPR214 Use of Multicriteria Decision Analysis (MCDA) for Includes Innovation in Public Health Policy Formulation: A Scoping Review

    Dec 1, 2024, 00:00

  • EE282 Budget Impact Analysis of Ivosidenib in Combination With Azacitidine for the Treatment of Previously Untreated mIDH1 Positive Acute Myeloid Leukaemia (AML) Patients, Ineligible for Intensive Induction Chemotherapy in Greece

    Dec 1, 2024, 00:00

  • EE636 Evaluating the Potential Health and Economic Impact of V116, an Adult Specific 21-Valent Pneumococcal Conjugate Vaccine, on Invasive Pneumococcal Disease in Spain

    Dec 1, 2024, 00:00

  • EE648 Micro-Costing Study of Comprehensive Genomic Profiling for Implementation of Precision Cancer Medicine in Public Healthcare Systems: The Norwegian Infrastructure for Precision Diagnostics and Impress-Norway Trial

    Dec 1, 2024, 00:00

  • EPH214 Epidemiological Disparities and Risk Factors of Esophageal Cancer in Türkiye: A Systematic Review

    Dec 1, 2024, 00:00

  • EE652 Budget Impact of Lecanemab for Alzheimer's Disease Patients Among Medicare Beneficiaries in the United States: A Subgroup Analysis

    Dec 1, 2024, 00:00

  • HPR153 Analysis of Annual-Cost Threshold for Drugs Reimbursement Decisions in China

    Dec 1, 2024, 00:00

  • CO109 Evaluating the Psychometric Properties of the Brazilian Portuguese EQ Health and Well-Being Short Form (EQ-HWB-S)

    Dec 1, 2024, 00:00

  • EE551 Cost-Minimization of Faricimab Vs Aflibercept 8 Mg in Patients With Neovascular Age-Related Macular Degeneration (nAMD): Evaluating the Impact of Retreatment Criteria

    Dec 1, 2024, 00:00

  • EE477 A Budget Impact Analysis of Introducing Filgotinib for the Treatment of Rheumatoid Arthritis in Greece

    Dec 1, 2024, 00:00

  • EE759 Cost-Effectiveness of Tezepelumab in Taiwan for Severe Asthma

    Dec 1, 2024, 00:00

  • HTA34 How Can the Marketing Authorization Holders Be Ready for the Implementation of the Joint Clinical Assessments in 2025?

    Dec 1, 2024, 00:00

  • Exploring the Association Between Surgical Out-of-Pocket Costs and Healthcare Quality Outcomes: A Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • HPR149 An Update on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reimbursed Under a Managed Access Protocol in Ireland

    Dec 1, 2024, 00:00

  • HTA158 A Comprehensive Review of NICE Highly Specialized Technology Appraisals

    Dec 1, 2024, 00:00

  • PT8 Access to Orphan Medicines in Ireland

    Dec 1, 2024, 00:00

  • EPH39 Economic Implications of Different Implementation Strategies for Collaborative Dementia Care Management in Terms of Patient Characteristics, Unmet Needs, and Cost-Effectiveness

    Dec 1, 2024, 00:00

  • HTA119 Assessing a Potential Framework to Prioritise Generalised Cost-Effectiveness Analysis (GCEA) Value Elements in Future Decision Making by Evidence and Relevan Case Study Across Oncology and Infectious Diseases

    Dec 1, 2024, 00:00

  • EPH251 Estimate of Brazilian Population in Secondary Prevention of Cardiovascular Disease in Public Healthcare System: Evaluating Potential Need for Lipid-Lowering Treatment Beyond Statin and Ezetimibe

    Dec 1, 2024, 00:00

  • HPR222 European Reimbursement Process Overview of Digital Medical Device

    Dec 1, 2024, 00:00

  • HTA166 Beyond RCTs: The Role of Real-World Evidence in NICE Submissions for Rare Diseases

    Dec 1, 2024, 00:00

  • HPR186 Developing a Value Framework to Determine New Drugs Price Premium Using Multi-Criteria Decision Analysis Approach: SFDA Experience

    Dec 1, 2024, 00:00

  • EPH161 Psychiatric Multimorbidity and Risk of Dementia: A 23-Year Cohort Study Using Akrivia Health Secondary Mental Healthcare Data

    Dec 1, 2024, 00:00

  • EE692 Uncovering the Blind Spot: A Targeted Search of Placebo Effect Adjustments in Submissions to the National Institute for Health and Care Excellence

    Dec 1, 2024, 00:00

  • The Cost-Effectiveness of Seizure Dogs for Persons Living With Severe Refractory Epilepsy: Results From the EPISODE Study

    Dec 1, 2024, 00:00

  • HSD6 Feasibility of Healthcare Quality Indicators for Breast Cancer in China: A Real-Word Study

    Dec 1, 2024, 00:00

  • HTA59 Assessing Efficiencies of AI-Powered Tools in Reporting Healthcare Economics and Outcomes Research (HEOR) Data for Health Technology Assessment (HTA) Submissions

    Dec 1, 2024, 00:00

  • HPR217 Analysis of Public Health Insurance Expenditures in Türkiye by Social Security Institution Between 2020 and 2023

    Dec 1, 2024, 00:00

  • EE592 Performance Evaluation of Explainable Artificial Intelligence to Replicate a Systematic Review and Meta-Analysis of Cost-Effectiveness Analysis Findings

    Dec 1, 2024, 00:00

  • HPR17 National Reimbursement Drug List in China: Changing Dynamics and Trend and Price Determination of Formulation Innovation Drugs

    Dec 1, 2024, 00:00

  • HTA230 Indirect Treatment Comparisons in NICE Highly Specialized Technology Assessments

    Dec 1, 2024, 00:00

  • EE793 An Early Economic Evaluation to Identify the Necessary Test Characteristics of Novel Biomarker Tests for Giant Cell Arteritis

    Dec 1, 2024, 00:00

  • HSD30 Hospital Methodology for Steering on Patient Value: Healthcare Outcomes in Relation to Costs

    Dec 1, 2024, 00:00

  • HTA207 Robotic Surgery in Oncology: Results From a Multidimensional Assessment in Italy

    Dec 1, 2024, 00:00

  • HSD84 Towards a Frictionless CAR-T Therapy Process: Identifying and Prioritizing Procedural Preconditions for Oncologic Institutions Using Group Concept Mapping

    Dec 1, 2024, 00:00

  • HTA170 Use of Off-Label Comparators in Health Technonology Assessment in Portugal: A Review of Reimbursement Appraisal Reports

    Dec 1, 2024, 00:00

  • HPR208 Does the Improvement of Medical Insurance Equity Enhance the Mental Health of Elderly Residents in Rural Areas? Evidence From the Adjustment of Medical Insurance Policy in China

    Dec 1, 2024, 00:00

  • PT13 Cost-Effectiveness Analysis of Stool-Based Colorectal Cancer Screening Tests for Individuals Aged 45 Years

    Dec 1, 2024, 00:00

  • EE783 Cost-Effectiveness Analysis of an Advanced Hybrid Closed Loop System Versus Standard of Care in the Management of Type 1 Diabetes in the Netherlands

    Dec 1, 2024, 00:00

  • EPH285 The Influence of Health Literacy on the Selection of Healthcare Facilities: An Association Between Health Literacy Level and Number of Healthcare Facilities Visited per Patient per Year Using Real World Data in Japan

    Dec 1, 2024, 00:00

  • EPH127 Drivers and Consequences of Plasma-Derived Medicinal Product Shortages

    Dec 1, 2024, 00:00

  • EE378 Health Economic Impact of Maternal Bivalent Stabilized Prefusion F Subunit Vaccine for Prevention of Respiratory Syncytial Virus Infections Among Infants in Germany

    Dec 1, 2024, 00:00

  • HTA183 A General Framework for Early Health Technology Assessment (eHTA) to Support the Development of New Radiology Artificial Intelligence (AI) Tools

    Dec 1, 2024, 00:00

  • HTA177 Reasons for Drug Market Access Failure in Portugal: A Retrospective Analysis of Public Reimbursement Reports

    Dec 1, 2024, 00:00

  • HPR236 Assessing the Reimbursement Landscape of Oncology Products in the Turkish Pharmaceutical Market

    Dec 1, 2024, 00:00

  • HTA12 The Cost-Effectiveness of Immunotherapies for Advanced or Recurrent Endometrial Cancer: A Systematic Review

    Dec 1, 2024, 00:00

  • HSD100 Economics of a Virtual Care Model for Diagnosis and Treatment of Sleep Apnea in Germany: Results From a Cost-Consequence Analysis

    Dec 1, 2024, 00:00

  • EPH57 Real-World Data of Severe Viral Lower Respiratory Tract Disease; Current Landscape, Challenges, and Future Recommendations

    Dec 1, 2024, 00:00

  • HSD38 Continuity of Medication Care for Cancer Patients Through Outpatient Service Provision in Specialist Practices in Germany

    Dec 1, 2024, 00:00

  • EE306 Comparison of Methods for Extrapolation of Drug Survival of Biologics in Psoriasis NICE Submission Cost-Effectiveness Analyses

    Dec 1, 2024, 00:00

  • EE355 The Impact of Dynamic Mortality on the Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in France

    Dec 1, 2024, 00:00

  • EPH63 Prevalence and Risks of Mental Health Issues During the Postnatal Period

    Dec 1, 2024, 00:00

  • EPH246 Comparison of Approval Dates of New Medications Between Europe (European Medicines Agency, EMA), Japan (Pharmaceutical and Medical Devices Agency, PMDA), and the United States (US) of America (Food and Drug Administration, FDA)

    Dec 1, 2024, 00:00

  • EE834 The Economic Impact of the Use of Two Flowable Hemostatic Matrices in Spinal Surgery in Three European Countries

    Dec 1, 2024, 00:00

  • EPH10 Dynamics of Self-Medication Among Expectant Mothers in a City in Southeast Nigeria

    Dec 1, 2024, 00:00

  • EPH284 Exploring the Association Between Health Literacy and Depression Prevalence Through Personal Health Record Associated With Health Insurance Claims Data

    Dec 1, 2024, 00:00

  • HTA112 Can Excess Hazard Models Enhance Survival Analysis in Health Technology Assessments?

    Dec 1, 2024, 00:00

  • HPR112 Access to Coverage With Evidence Development Schemes for Medical Devices and Procedures in England, France, Germany, Spain, and the USA

    Dec 1, 2024, 00:00

  • EE325 Hospitalizations From Veno-Occlusive Disease in the US Pacific Region: A Six-Cohort Analysis of National In-Patient Data (2016-2020)

    Dec 1, 2024, 00:00

  • P60 Socioeconomic Burden of Major Diseases in Eight Latin American Countries

    Dec 1, 2024, 00:00

  • EE275 Real-World Healthcare Resource Utilization and Costs in Patients With Locally Advanced or Metastatic Urothelial Carcinoma in China

    Dec 1, 2024, 00:00

  • EE563 Considerations for Health Economic Modelling in a Crowded Treatment Landscape: Lessons From Recent Models for Psoriasis, Psoriatic Arthritis, and Ulcerative Colitis

    Dec 1, 2024, 00:00

  • PT16 Economic Influences on Medical Decision-Making in Cancer Medicine: An Analysis of Qualitative and Quantitative Data

    Dec 1, 2024, 00:00

  • HSD121 Change in Metabolic Syndrome of the Primary Care-Based National Lifestyle Intervention Program: An Observation Cohort Study

    Dec 1, 2024, 00:00

  • Evidence Quality and Health Technology Assessment Outcomes in Reappraisals of Drugs for Rare Diseases in Germany

    Dec 1, 2024, 00:00

  • EPH26 New Pattern in Esophoria Incidence Identified by Linear Splines

    Dec 1, 2024, 00:00

  • EE637 Assessment of Clinically Meaningful Benefits and Incremental Costs of Adding Bevacizumab to Trifluridine/Tipiracil for Metastatic Colorectal Cancer: A Comparison With Other Combination Regimens

    Dec 1, 2024, 00:00

  • HSD40 Therapeutic Decision-Making for Patients With Sickle Cell Disease (SCD) and How Research Findings Influence the Potential Use of Mitapivat

    Dec 1, 2024, 00:00

  • EPH23 The Use of Machine Learning Techniques for Healthcare Cost Prediction: A Preliminary Analysis of Administrative Databases From a Health Protection Agency in Northern Italy

    Dec 1, 2024, 00:00

  • EPH150 Associations Between Co-Occurring Mental Disorders and Treatment Completion Among Women of Reproductive Age Admitted for Cannabis Dependen Evidence From the United States Treatment Episode Data Set

    Dec 1, 2024, 00:00

  • EE588 Direct Costs of RSV Cases in Hospitalized Patients (Aged ≥60 Years) Identified From 2010-2020 in a Retrospective Study in Valladolid, Spain

    Dec 1, 2024, 00:00

  • EE789 Cost-Effectiveness of Tirzepatide Versus Liraglutide (Both Adjunct to a Reduced-Calorie Diet and Increased Physical Activity) in Patients With Obesity or Overweight From a UK Perspective

    Dec 1, 2024, 00:00

  • HTA82 A Blueprint for Success: The Importance of Multi-Stakeholder Alignment for EU Health Technology Assessment (HTA)

    Dec 1, 2024, 00:00

  • EE416 Cost-Effectiveness Analysis of Nirsevimab Prophylaxis for Prevention of Respiratory Syncytial Virus Disease Among Infants in South Korea

    Dec 1, 2024, 00:00

  • EE790 Cost-Effectiveness and Cost Utility Analysis of an eHealth Peer-Led Wheelchair Training Program Compared to the Existing Wheelchair Training Practice in Canadian Rehabilitation Centers: Economic Evaluation of a RCT

    Dec 1, 2024, 00:00

  • CO15 Real-World Treatment Usage of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Belgium: Results of the AREVEDECY Study

    Dec 1, 2024, 00:00

  • EE724 Healthcare Resources Utilization and Costs of Treatment Associated With Anogenital Warts in South Africa: Public and Private Perspective

    Dec 1, 2024, 00:00

  • HSD9 Development of a Framework for a Networked Service Model for the Care of Adults With Rare Bone Conditions: Healthcare Professional Survey for X-Linked Hypophosphataemia (XLH)

    Dec 1, 2024, 00:00

  • CO56 Retrospective Non-Interventional Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette-Guerin in Patients With Non-Muscle-Invasive Bladder: Real-World Experience From Six Hospital Centers in Greece

    Dec 1, 2024, 00:00

  • EPH125 How Do We Refer to Individuals in the Scientific Literature? Use of 'Person-First' Language vs 'Condition-First' Language in Oncology Medical Journals

    Dec 1, 2024, 00:00

  • HTA10 HTA Considerations for Large Language Models in Healthcare

    Dec 1, 2024, 00:00

  • CO122 Pharmacist-Driven Management of Type 2 Diabetes Improves HbA1c, Mortality, and Medical Costs in an Integrated Health System

    Dec 1, 2024, 00:00

  • EE439 A Multiple Myeloma Case Study for Incorporating Carbon Footprint in Health Technology Assessment

    Dec 1, 2024, 00:00

  • EE247 Fully Replicating Published Markov Health Economic Models Using Generative AI

    Dec 1, 2024, 00:00

  • EE838 Cost-Effectiveness of Momelotinib for Treatment of Myelofibrosis in Taiwan

    Dec 1, 2024, 00:00

  • HPR250 Reimbursement Decisions for Innovative Drug Technologies in Poland: Duration of Reimbursement Processes and Impact of HTA Recommendation

    Dec 1, 2024, 00:00

  • HSD90 Towards Tomorrow: Transforming Sarcoma Care in Bulgaria

    Dec 1, 2024, 00:00

  • HPR230 Overview of the Past and Future Development of Novel Antibiotics in Fran Is It Sufficient to Tackle Antimicrobial Resistance?

    Dec 1, 2024, 00:00

  • EE713 Cost-Effectiveness of Adjuvant Nivolumab for Patients With Stage III and IV Melanoma Who Have Undergone Complete Resection in Austria

    Dec 1, 2024, 00:00

  • CO130 Outcomes and Economic Effects of Digital Health Services: An Umbrella Review

    Dec 1, 2024, 00:00

  • HTA102 Are EU JCA Evidence Requirements Achievable? Insights From a Retrospective Evidence Analysis Study for Rare and Non-Rare EU Treatment Landscapes

    Dec 1, 2024, 00:00

  • HPR32 Assessing the Health Outcomes and Additional Budget Impact of PD-(L)1 Inhibitors in the Early Stages of Cancer Treatment in Greece

    Dec 1, 2024, 00:00

  • HSD39 Beliefs and Behaviors of Healthcare Workers Towards Influenza Vaccination: A Systematic Review

    Dec 1, 2024, 00:00

  • EE241 Fondaparinux: A Cost-Saving Alternative to Low-Molecular-Weight Heparins for Venous Thromboembolic Event Prevention/Treatment and Acute Coronary Syndrome Treatment

    Dec 1, 2024, 00:00

  • P45 Optimizing Electronic Medical Records Data Completeness With On-Premise Artificial Intelligen A Study on Large Language Models Enhancing Medication Documentation

    Dec 1, 2024, 00:00

  • EPH165 Modeling Respiratory Syncytial Virus Burden and Public Health Impact of RSVPreF3 Vaccine Among Adults Aged ≥60 Years Old in Five Countries in South East Asia

    Dec 1, 2024, 00:00

  • EPH89 Medical Costs of Adults With COVID-19 in Costa Rica During the Endemic Phase: A Micro-Costing Study

    Dec 1, 2024, 00:00

  • EPH249 Epidemiology of Patients With Thymic Carcinoma in the United States: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • PT19 Emerging Trends in the Adoption of Alternative Financing Models for Advanced Therapy Medicinal Products: A Scoping Review

    Dec 1, 2024, 00:00

  • EE680 Estimating the Potential Lifetime Health and Economic Impact of V116, an Adult Specific 21-Valent Pneumococcal Conjugate Vaccine, on Invasive Pneumococcal Disease in the Netherlands

    Dec 1, 2024, 00:00

  • EE472 The Burden-of-Illness of Duchenne Muscular Dystrophy in Japan: A Socioeconomic Survey

    Dec 1, 2024, 00:00

  • EE450 Economic Burden of People Living With HIV in China: An Analysis Based on Real-World Medical Database

    Dec 1, 2024, 00:00

  • EE354 An Exploratory Cost-Effectiveness Analysis of Cancer Vaccines in Combination With Current Immune Checkpoint Inhibitors Vs Immune Checkpoint Inhibitor Monotherapy: A Case Study for V940 in High-Risk Stage 3 Melanoma in the US

    Dec 1, 2024, 00:00

  • HSD78 Potentially Inappropriate Medication Use Among Dual-Eligible Beneficiaries With Dementia by Medicare Enrollment Type

    Dec 1, 2024, 00:00

  • HTA182 Evaluating the Use, Performance, and Acceptability of Utility Measurement Approaches in Geographic Atrophy: A Severe Vision Disorder

    Dec 1, 2024, 00:00

  • HTA101 Inequities in COPD Treatment Access Across Brazilian Municipalities: A Population-Based Analysis

    Dec 1, 2024, 00:00

  • EE489 Cost-Effectiveness of Zanubrutinib + Obinutuzumab for Treatment of Relapsed or Refractory Follicular Lymphoma in the United States

    Dec 1, 2024, 00:00

  • HTA171 The Use and Influence of Real-World Evidence on French Health Technology Assessments

    Dec 1, 2024, 00:00

  • HTA24 What Key Areas of Clinical and Economic Uncertainty Have Scottish Medicines Consortium (SMC) Identified in Ultra-Orphan Initial Assessments to Date?

    Dec 1, 2024, 00:00

  • EPH53 The Indirect Costs Related to HPV-Attributable Cancer Mortality in European Countries; Years of Life Lost, and Productivity Costs

    Dec 1, 2024, 00:00

  • HPR145 The Evolving Influence of the Inflation Reduction Act and Value Assessment in US Payer Decision-Making

    Dec 1, 2024, 00:00

  • CO49 Evaluating Efficacy and Safety of RNA Therapies Lumasiran and Nedosiran in Patients With Primary Hyperoxaluria Type 1: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • CO66 A Systematic Review of Pharmacological Interventions for Hidradenitis Suppurativa: A Focus on Clinical Response, Quality of Life, and Safety

    Dec 1, 2024, 00:00

  • Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A Duchenne Muscular Dystrophy Case Study [Editor's Choice]

    Dec 1, 2024, 00:00

  • HTA130 Key Drivers Underlying Positive and Negative Decisions for National Institute for Health and Care Excellence (NICE) Technology Appraisals (TAS) and Highly Specialised Technology (HST) Appraisals in 2023

    Dec 1, 2024, 00:00

  • EE779 Internal Validation of the Metabo-Reno-Cardiovascular Disease Model: Risk of Recurrent Cardiovascular Events in a Population With and Without Diabetes

    Dec 1, 2024, 00:00

  • EPH36 Evaluation of the Impact of Herpes Zoster Vaccination in 18 to 49 Years Old German Patients With Immunosuppression on Public Health Measures

    Dec 1, 2024, 00:00

  • HTA100 How Do Abbreviated HTA Submissions Impact Reimbursement? A SMC Case Study

    Dec 1, 2024, 00:00

  • HSD54 Epidemiology, Healthcare Resource Utilization, and Costs of Hemophilia A and B by Treatment Regimen: A Retrospective Claims Data Analysis in Germany From 2016 to 2021

    Dec 1, 2024, 00:00

  • EE310 Evaluating Cost Outcomes Across Three Methods for Incorporating Time-to-Event Outcomes in Budget Impact Analyses

    Dec 1, 2024, 00:00

  • HPR243 Insights Into the Oncology and Allied Digital Health Landscape on the Island of Ireland: Implications for Policy and Practice

    Dec 1, 2024, 00:00

  • EE786 QoL Data in CAR-T Cost-Effectiveness Analysis (CEA) in Fran What to Use?

    Dec 1, 2024, 00:00

  • EPH176 Controlling RSV in Older Adults: Clinical Benefits of a Dutch Vaccination Program

    Dec 1, 2024, 00:00

  • EE243 Cost-Effectiveness Analysis of Penpulimab Plus Paclitaxel and Carboplatin Combination Therapy As First-Line Therapy for Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer

    Dec 1, 2024, 00:00

  • HPR79 The Turning Point of Substance Use Among Disadvantaged Young People in England: A Mediation Analysis

    Dec 1, 2024, 00:00

  • EE604 A Multi-State Model to Assess the Impact of Ruxolitinib in Extending Failure Free Survival and Life Expectancy in Patients With Steroid-Refractory Acute Graft vs Host Disease

    Dec 1, 2024, 00:00

  • CO42 Comparison of Survival Outcomes for [177Lu]Lu-PSMA-617 vs Other Systemic Treatments in Post-Taxane Metastatic Castration-Resistant Prostate Cancer Setting: A Bayesian Network Meta-Analysis

    Dec 1, 2024, 00:00

  • HTA216 Navigating Prospective PICO Consolidation in Oncology: Insights From Retrospective Simulations for Crowded and Non-Crowded EU Treatment Landscapes

    Dec 1, 2024, 00:00

  • HPR26 Managed Entry Agreements to Mitigate Uncertainties and Reimbursement Challenges for Orphan Drugs: A Matrix to Determine Their Suitability

    Dec 1, 2024, 00:00

  • EE548 Cost-Effectiveness Analysis of Epcoritamab for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy in Greece

    Dec 1, 2024, 00:00

  • EE616 Cost of Illness Study of Inherited Retinal Diseases in the Netherlands in 2023

    Dec 1, 2024, 00:00

  • CO110 A Systematic Literature Review and Network Meta Analysis of Insulin Icodec With Other Basal Insulins in Patients With Type 2 Diabetes Switching From Basal Insulin Regimens

    Dec 1, 2024, 00:00

  • HTA143 A Review on the Role of Comparators in French Health Technology Assessments

    Dec 1, 2024, 00:00

  • HSD104 Care Integration With Telemedicine for Remote Monitoring of Pressure Ulcers in Home Care Patients

    Dec 1, 2024, 00:00

  • EE267 Cost Effectiveness and Budget Impact of the Recombinant Zoster Vaccine Among Older Adults in Singapore

    Dec 1, 2024, 00:00
  • 1
  • 2 (current)
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »